Literature DB >> 1510437

Removal of vancomycin by high-flux hemodialysis membranes.

J M Quale1, J J O'Halloran, N DeVincenzo, R H Barth.   

Abstract

Levels of vancomycin in serum are traditionally believed to be unaffected by hemodialysis. By both in vivo and in vitro techniques, the effects of a newer, more permeable dialyzer membrane on vancomycin concentrations were investigated. Six patients who were receiving vancomycin and undergoing maintenance hemodialysis with polyacrylonitrile dialyzer membranes had postdialysis levels in serum that were 63% of predialysis levels; the intradialytic half-life was 5.7 h. Vancomycin concentrations in serum exiting the dialyzer were 68% of those simultaneously entering the dialyzer at the beginning of dialysis. When polyacrylonitrile and conventional cellulose membranes were perfused in vitro with a recirculating solution of vancomycin, vancomycin concentrations fell to 39 and 91%, respectively, of the original concentration. The vancomycin concentration in the ultrafiltrate collected from the polyacrylonitrile membranes was only 23% of the original perfusate concentration. A significant decrease in the serum vancomycin concentration may occur during hemodialysis with newer high-flux dialyzer membranes. It appears that vancomycin binds to polyacrylonitrile membranes; this binding does not require the presence of protein and is affected by the pH of the perfusate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510437      PMCID: PMC191597          DOI: 10.1128/AAC.36.7.1424

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Inaccurate blood flow rate during rapid hemodialysis.

Authors:  D F Schmidt; B J Schniepp; S B Kurtz; J T McCarthy
Journal:  Am J Kidney Dis       Date:  1991-01       Impact factor: 8.860

2.  Vancomycin dosing chart for use in patients with renal impairment.

Authors:  D L Brown; L S Mauro
Journal:  Am J Kidney Dis       Date:  1988-01       Impact factor: 8.860

3.  Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.

Authors:  D M Lanese; P S Alfrey; B A Molitoris
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

4.  Pharmacokinetics of vancomycin in anuria.

Authors:  B A Cunha; R Quintiliani; J M Deglin; M W Izard; C H Nightingale
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

5.  Structural features of vancomycin.

Authors:  R R Pfeiffer
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

6.  Drug elimination by hemofiltration.

Authors:  K W Rumpf; J Rieger; B Doht; R Ansorg; F Scheler
Journal:  J Dial       Date:  1977

7.  Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

8.  Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure.

Authors:  C C Tan; H S Lee; T Y Ti; E J Lee
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

9.  Persistent staphylococcal bacteremia in an intravenous drug abuser.

Authors:  N L Barg; R B Supena; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

10.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  7 in total

1.  The serum vancomycin assay: A test of historic interest.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1995-03

2.  Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.

Authors:  F Thalhammer; P Schenk; H Burgmann; I El Menyawi; U M Hollenstein; A R Rosenkranz; G Sunder-Plassmann; S Breyer; K Ratheiser
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Treatment of paediatric vancomycin intoxication: a case report and review of the literature.

Authors:  Mathieu Lemaire; Bairbre Connolly; Elizabeth Harvey; Christoph Licht
Journal:  NDT Plus       Date:  2010-03-17

4.  Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies.

Authors:  Dariusz Onichimowski; Hubert Ziółkowski; Krzysztof Nosek; Jerzy Jaroszewski; Elżbieta Rypulak; Mirosław Czuczwar
Journal:  J Artif Organs       Date:  2019-10-20       Impact factor: 1.731

5.  Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study.

Authors:  Dariusz Onichimowski; Krzysztof Nosek; Hubert Ziółkowski; Jerzy Jaroszewski; Aleksandra Pawlos; Mirosław Czuczwar
Journal:  J Artif Organs       Date:  2020-10-08       Impact factor: 1.731

6.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388

7.  Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role.

Authors:  Xiao Li; Wen Xu; Ran Li; Qie Guo; Xiangpeng Li; Jialin Sun; Shuhong Sun; Jing Li
Journal:  Infect Drug Resist       Date:  2021-07-02       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.